Case Report: Subacute cutaneous lupus erythematosus induced by the anti-PD-1 antibody camrelizumab combined with chemotherapy
Camrelizumab treatment may be associated with the appearance of subacute cutaneous lupus erythematosus in sun-exposed skin regions, which can be rapidly relieved by local and systemic glucocorticoids and hydroxychloroquine. It is recommended to perform early antibody testing and skin biopsy for diagnosis and treatment. Unlike classic drug-related SCLE, patients may develop multiple autoimmune diseases, and caution should be taken when using immune checkpoint inhibitors for subsequent treatment.
Authors
- Jiazhu Hu (ORCID: https://orcid.org/0009-0002-0270-360X)
- Xiaolong Cao (ORCID: https://orcid.org/0000-0001-8124-7491)
- Xiaojing Song (ORCID: https://orcid.org/0000-0002-9382-285X)
- Xi Luo (ORCID: https://orcid.org/0009-0008-7838-1997)
- Fang Chen (ORCID: https://orcid.org/0000-0001-7531-4264)
- Juan Li (ORCID: https://orcid.org/0000-0003-3317-2709)
- Hehong Bao
- Hejing Bao (ORCID: https://orcid.org/0000-0002-6090-9844)
- Ning Mao (ORCID: https://orcid.org/0000-0003-0431-9222)
- Liping Lin (ORCID: https://orcid.org/0009-0003-8741-263X)
- Jiani Zhang
- Shudong Ma
Institutions
- Chongqing University (CN)
- Shenzhen University (CN)
- Panyu Hospital of Chinese Medicine (CN)
- Nanfang Hospital (CN)
- Chongqing Three Gorges University (CN)
- Southern Medical University (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-03-28
- DOI
- https://doi.org/10.3389/fimmu.2025.1539373
- Citations
- 1
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 1.67